Significance of GABAergic systems in the action of improgan, a non-opioid analgesic

Life Sciences

Volumn 68, Issue 24, 2001, Pages 2751-2757

  Hough, L B ^a   Nalwalk, J W ^a   Leurs, R ^b   Menge, W M P B ^b   Timmerman, H ^b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

Analgesia; Antinociception; GABA; Histamine; Improgan; Muscimol; Opioids; Receptors

Indexed keywords

4 AMINOBUTYRIC ACID A RECEPTOR; ANALGESIC AGENT; IMPROGAN; MORPHINE; MUSCIMOL; OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; GABAERGIC SYSTEM; MALE; NONHUMAN; RAT; TAIL FLICK TEST;

ANALGESICS, NON-NARCOTIC; ANIMALS; CIMETIDINE; GAMMA-AMINOBUTYRIC ACID; MALE; MORPHINE; MUSCIMOL; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA-A;

EID: 0035805202     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(01)01080-3     Document Type: Article

References (25)

1. Hough LB, Nalwalk JW, Barnes WG, Warner LM, Leurs R, Menge WMPB, Timmerman H, Wentland M. A third life for Burimamide: Discovery and characterization of a novel class of non-opioid analgesics derived from histamine antagonists. In: Glick SD, Maisonneuve IM, editors: New Medications for Drug Abuse. New York: New York Acad. Sci., 2000. pp. 25-40.
2. Li BY, Nalwalk JW, Hough LB. Effects of naltrexone and histamine antagonists on the antinociceptive activity of the cimetidine analog SKF92374 in rats. Brain Res. 1997; 748:168-174.
3. Li BY, Nalwalk JW, Barker LA, Cumming P, Parsons ME, Hough LB. Characterization of the antinociceptive properties of cimetidine and a structural analog. J.Pharmacol.Exp.Ther. 1996; 276:500-508.
4. Li BY, Nalwalk JW, Finkel JM, Glick SD, Hough LB. SKF92374, a cimetidine analog, produces mechanical and thermal antinociception in the absence of motor impairment. Analgesia 1997; 3:15-20.
5. Bannoura MD, Nalwalk JW, Tang Y, Carlile M, Leurs R, Menge WMPB, Timmerman H, Hough LB. Absence of antinociceptive tolerance to improgan, a cimetidine analog, in rats. Brain Res. 1998; 814:218-221.
6. 3 antagonists and derivatives. J.Pharmacol.Exp.Ther. 1997; 283:1534-1543.
7. Hough LB, Nalwalk JW, Leurs R, Menge WMPB, Timmerman H. Antinociceptive activity of derivatives of improgan and burimamide. Pharmacol.Biochem.Behav. 2000; 65:61-66.
8. Hough LB, Nalwalk JW, Leurs R, Menge WMPB, Timmerman H. Antinociceptive activity of impentamine, a histamine congener, after CNS administration. Life Sci. 1999; 64:PL79-PL86.
9. Hough LB, Nalwalk JW, Chen Y, Schuller A, Zhu Y, Zhang J, Menge WMPB, Leurs R, Timmerman H, Pintar JE. Improgan, a cimetidine analog, induces morphine-like antinociception in opioid receptor-knockout mice. Brain Res. 2000; 880:102-108.
10. Fields HL, Heinricher MM, Mason P. Neurotransmitters in nociceptive modulatory circuits. Annu.Rev.Neurosci. 1991; 14:219-245.
11. Beitz AJ. Anatomic and chemical organization of descending pain modulation systems. In: Short CE, Poznak AV editors: Animal Pain. New York: Churchill Livingston,1992. pp. 31-62.
12. Mitchell JM, Lowe D, Fields HL. The contribution of the rostral ventromedial medulla to the antinociceptive effects of systemic morphine in restrained and unrestrained rats. Neurosci. 1998; 87:123-133.
13. Roychowdhury SM, Fields HL. Endogenous opioids acting at a medullary μ-opioid receptor contribute to the behavioral antinociception produced by GABA antagonism in the midbrain periaqueductal gray. Neurosci. 1996; 74:863-872.
14. Mantegazza P, Tammiso R, Vicentini L, Zambotti F, Zonta N. Muscimol antagonism of morphine analgesia in rats. Br.J.Pharmacol. 1979; 67:103-107.
15. Depaulis A, Morgan MM, Liebeskind JC. GABAergic modulation of the analgesic effects of morphine microinjected in the ventral periaqueductal grey matter of the rat. Brain Res. 1987; 436:223-228.
16. Zonta N, Zambotti F, Vicentini L, Tammiso R, Mantegazza P. Effects of some GABA-mimetic drugs on the antinociceptive activity of morphine and β-endorphin in rats. Naunyn Schmiedebergs Arch.Pharmacol. 1981; 316:231-234.
17. Vaughan CW, Ingram MA, Connor MA, Christie MJ. How opioids inhibit GABA-mediated neurotransmission. Nature 1997; 390:611-614.
18. Meng ID, Manning BH, Martin WJ, Fields HL. An analgesia circuit activated by cannabinoids. Nature 1998; 395:381-383.
19. Crane LA, Glick SD. Simple cannula for repeated intracerebral drug administration in rats. Pharmacol.Biochem.Behav. 1979; 10:799-800.
20. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. Sydney: Academic Press, 1986.
21. D'Amour FE, Smith DL. A method for determining loss of pain sensation. J.Pharmacol.Exp.Ther. 1941; 72:74-79.
22. Renno WM, Mullett MA, Beitz AJ. Systemic morphine reduces GABA release in the lateral but not the medial portion of the midbrain periaqueductal gray of the rat. Brain Res. 1992; 594:221-232.
23. Stiller CO, Bergquist J, Beck O, Ekman R, Brodin E. Local administration of morphine decreases the extracellular level of GABA in the periaqueductal gray matter of freely moving rats. Neurosci.Lett. 1996; 209: 165-168.
24. Hough LB. Histamine. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhlén S editors: Basic Neurochemistry: Molecular, Cellular and Medical Aspects. Philadelphia: Lippincott-Raven,1999. pp. 293-313.
25. Oda T, Morikawa N, Saito Y, Masuho Y, Matsumoto S. Molecular cloning and characterization of novel type of histamine receptor preferentially expressed in leukocytes. J.Biol.Chem. in press, 2000.